Evaluation of Analgesic and Anti-Inflammatory Activities of Water Extract of Galla Chinensis In Vivo Models.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Hindawi Pub Country of Publication: United States NLM ID: 101215021 Publication Model: eCollection Cited Medium: Print ISSN: 1741-427X (Print) Linking ISSN: 1741427X NLM ISO Abbreviation: Evid Based Complement Alternat Med Subsets: PubMed not MEDLINE
    • Publication Information:
      Publication: 2011- : New York, NY : Hindawi Pub.
      Original Publication: Oxford, UK : Oxford University Press, c2004-
    • Abstract:
      Aim: Pain and inflammation are associated with many diseases in humans and animals. Galla Chinensis , a traditional Chinese medicine, has a variety of pharmacological properties. The purpose of this study was to evaluate analgesic and anti-inflammatory activities of Galla Chinensis through different animal models.
      Method: The analgesic activities were evaluated by hot-plate and writhing tests. The anti-inflammatory effects were assessed by ear edema, capillary permeability, and paw edema tests. The contents of cytokines (NO, iNOS, PGE 2 , and IL-10) in serum of rats in paw edema test were inspected by ELISA assays.
      Results: In the hot-plate test, Galla Chinensis could significantly extend pain threshold when compared to control group. The inhibitory rates of writhes ranged from 36.62% to 68.57% in Galla Chinensis -treated mice. Treatment with Galla Chinensis (1 and 0.5 g/kg) could significantly inhibit ear edema (47.45 and 36.91%, resp.; P < 0.01). Galla Chinensis (1 g/kg) had significant ( P < 0.05) anti-inflammatory activity in capillary permeability test (29.04%). In carrageenan-induced edema test, the inhibitory rates were 43.71% and 44.07% ( P < 0.01) at 1 h and 2 h after administration of Galla Chinensis (1 g/kg), respectively, and the levels of proinflammatory cytokines were significantly reduced.
      Conclusion: These results suggest that Galla Chinensis has analgesic and anti-inflammatory effects, which may be a candidate drug for the treatment of inflammation and pain.
    • References:
      J Nat Med. 2015 Jul;69(3):324-31. (PMID: 25762161)
      Cell Immunol. 2004 Apr;228(2):99-109. (PMID: 15219461)
      J Immunol. 1995 Mar 15;154(6):2668-77. (PMID: 7533180)
      Br J Pharmacol Chemother. 1968 Feb;32(2):295-310. (PMID: 4230818)
      Naunyn Schmiedebergs Arch Pharmacol. 1990 Aug;342(2):189-93. (PMID: 2234103)
      Int Immunopharmacol. 2013 Mar;15(3):505-10. (PMID: 23415748)
      Arch Oral Biol. 2012 Aug;57(8):1093-9. (PMID: 22621905)
      Br J Nutr. 2011 Jan;105(1):31-43. (PMID: 21073761)
      Inflammopharmacology. 2010 Aug;18(4):187-96. (PMID: 20390366)
      Inflammation. 2015 Apr;38(2):923-33. (PMID: 25373916)
      J Ethnopharmacol. 2004 Jun;92(2-3):263-7. (PMID: 15138010)
      J Ethnopharmacol. 2009 Jun 25;123(3):510-4. (PMID: 19443147)
      Oral Microbiol Immunol. 2008 Dec;23(6):459-65. (PMID: 18954351)
      Nature. 2002 Dec 19-26;420(6917):846-52. (PMID: 12490957)
      Nature. 1964 Oct 10;204:189-90. (PMID: 14222271)
      J Ethnopharmacol. 2015 Jun 20;168:217-28. (PMID: 25839115)
      Eur J Pharmacol. 1980 Jan 11;61(1):17-24. (PMID: 7353582)
      J Ethnopharmacol. 2009 Sep 7;125(2):297-303. (PMID: 19576980)
      J Ethnopharmacol. 2008 Sep 2;119(1):6-11. (PMID: 18675525)
      Chin J Integr Med. 2013 May;19(5):394-400. (PMID: 23674113)
      J Med Food. 2010 Aug;13(4):888-95. (PMID: 20482259)
      J Nat Med. 2015 Jan;69(1):22-34. (PMID: 25227288)
      Evid Based Complement Alternat Med. 2014;2014:350507. (PMID: 25045389)
      Asian Pac J Trop Biomed. 2015 Nov;5(11):921-927. (PMID: 32363148)
      Planta Med. 1990 Oct;56(5):430-4. (PMID: 1981810)
      Int J Mol Sci. 2013 Jan 30;14(2):2928-45. (PMID: 23364614)
      J Ethnopharmacol. 2011 Jun 1;135(3):654-61. (PMID: 21501676)
      J Ethnopharmacol. 2012 May 7;141(1):322-30. (PMID: 22401764)
    • Publication Date:
      Date Created: 20180420 Latest Revision: 20240313
    • Publication Date:
      20240313
    • Accession Number:
      PMC5835261
    • Accession Number:
      10.1155/2018/6784032
    • Accession Number:
      29670660